Who were biopharma's Q4 growth stars? Vertex, thanks to a new launch, plus Alexion, Regeneron and GSK

Several of the industry's top players turned in a strong performance in the fourth quarter, growing revenues at high single-digit rates, an analysis shows. Others? Not so much.

No company posted growth as high as Vertex's, which is riding a hot new launch for cystic fibrosis combination med Trikafta. Of course, Vertex doesn't have quite the heft of the biopharma industry's top players, so adding a big new launch to its existing revenue really bolstered its numbers.